Login to Your Account



ImClone’s Erbitux Receives FDA Label In Head And Neck Cancer

By Randall Osborne


Friday, March 3, 2006
ImClone Systems Inc. stands to get a $250 million milestone payment from partner Bristol-Myers Squibb Co., thanks to the FDA’s approval of the colorectal cancer drug Erbitux for the added indication of head and neck cancer. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription